Ascletis Announces IND Filing of Its Second FASN Inhibitor ASC60 for Advanced Solid Tumors Accepted by China NMPA

HANGZHOU, China and SHAOXING, China, Jan. 26, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) today announces that following the consultation with China National Medical Products Administration (NMPA),...

Full "IntellAsia: Resources" article